Skip to content

The Effect of Using High-flow Nasal Oxygen-delivery System in Patients Under Intravenous General Anesthesia

The Effect of Using High-flow Nasal Oxygen-delivery System in Patients Under Intravenous General Anesthesia

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03019354
Enrollment
60
Registered
2017-01-12
Start date
2017-01-31
Completion date
2019-01-31
Last updated
2018-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Atelectases, Lung Injury, General Anesthesia

Keywords

high flow oxygen, pulmonary atelectasis, intravenous general anesthesia

Brief summary

In general anesthesia, gas exchange was altered by shunt and uneven ventilation perfusion ratios. Lung atelectasis was a cause of impaired oxygenation. High-flow nasal cannula oxygen therapy delivers adequately heated and humidified medical gas at up to 60 L/min of flow. It has physiological effects: reduction of anatomical dead space, positive end expiratory pressure (PEEP) effect, constant fraction of inspired oxygen, and good humidification. The hypothesis of this study is using high-flow nasal oxygen in intravenous general anesthesia could improve lung function and prevent lung atelectasis.

Detailed description

After general anesthesia, almost 90% patients have lung atelectasis. The lung atelectasis persisted even after the surgery, and caused post operative complication, for example: fever, pleural effusion, hypoxemia, pneumonia, and respiratory failure. So, how to improve lung function after the surgery is a important issue. High-flow nasal cannula oxygen therapy delivers adequately heated and humidified medical gas at up to 60 L/min of flow. It provides respiratory support: 1. Reduction of dead Space by clearance of expired air in the upper airways. 2. Delivering positive airway pressure. 3. delivering optimal humidity, which helps maintain function of the mucociliary transport system, clearing secretions and reducing the risk of infections. Many reports suggest that high-flow nasal cannula decreases breathing frequency and work of breathing and reduces intubation rate in critical ill patients. Although high-flow nasal cannula was used widely in intensive care unit (ICU) , there are no enough evidence in patients under general anesthesia. The hypothesis of this study is that using high-flow nasal oxygen in intravenous general anesthesia could improve lung function and prevent lung atelectasis. Liver tumor radiofrequency ablation was performed sometimes in patients under general anesthesia. Intravenous general anesthesia is one of the anesthesia choice. Oxygen mask is the traditional oxygen delivery system. Apnea, hypoxemia, and CO2 retention are common situation in intravenous general anesthesia. So high-flow nasal oxygen is an ideal oxygen delivery system in intravenous general anesthesia. This randomized control study will enroll patients receiving CT guided liver tumor radiofrequency ablation under general anesthesia. One group will receive high-flow nasal oxygen, the other group will receive traditional oxygen mask. The primary outcome is lung atelectasis area in CT scan. The secondary outcome is respiratory function (for example: arterial blood gas, lung injury biomarkers, saturation, postoperative pulmonary complication)

Interventions

Using high-flow nasal oxygen 10 L/min before anesthesia induction, then using high-flow nasal oxygen 30-50 L/min during intravenous general anesthesia.

Using oxygen mask with oxygen flow 10 L/min before and during intravenous general anesthesia.

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with hepatic tumor undergoing CT guided radiofrequency ablation * Age \> 20 years old

Exclusion criteria

* Cardiac dysfunction, such as heart failure \> NYHA class II, coronary arterial disease * Impaired renal function, cGFR\< 60 ml/min/1.73 m2 * Pulmonary disease

Design outcomes

Primary

MeasureTime frameDescription
Chest CT image atelectatic areaAt the end of surgerylung atelectasis (-100 to +100 Hounsfield Unit) was calculated and as percent of the total area of the lung at the basal scan.

Secondary

MeasureTime frameDescription
postoperative pulmonary complicationswithin the first 7 days after surgerypostoperative pulmonary complications including pneumonia, pleural effusion, and acute lung injury.
lung injuryAt the end of surgerylung injury biomarkers including Clara cell protein, Plasma neutrophil elastase.

Other

MeasureTime frameDescription
Respiratory gas exchange functionAt the end of surgeryblood gas analysis including PaO2, PaCO2
need for supplemental oxygen therapywithin the first 7 days after surgery

Countries

Taiwan

Contacts

Primary ContactChung-Chih Shih, MD
s6319138@gmail.com+886 911674300
Backup ContactChung-Chih Shih, MD
s6319138@hotmail.com+886 972653379

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026